Newsroom
Sorted by: Latest
-
Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today reported its first quarter 2026 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update. “This quarter, we continued to build on our developmental and clinical acc...
-
Super Group to Participate in Upcoming Investor Conferences
NEW YORK--(BUSINESS WIRE)--Super Group (SGHC) Limited (NYSE: SGHC) (“SGHC”, the "Company" or “Super Group”), the parent company of Betway, a leading online sports betting and gaming business, and Spin, the multi-brand online casino, today announced that management will attend the following upcoming investor conferences and events: 21st Annual Needham Technology, Media, & Consumer Conference May 14, 2026 – Virtual Attendees: Neal Menashe, Chief Executive Officer, Alinda Van Wyk, Chief Financ...
-
Quanterix Announces Planned Transition of Chief Financial Officer
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that Vandana Sriram, its Chief Financial Officer (“CFO”) will depart the Company. A search for her successor is ongoing, and Ms. Sriram will continue as CFO through June 15, 2026, to ensure continuity and a successful transition. "Vandana has made impactful contributions to Quanterix since joining the Co...
-
TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended March 31, 2026, and provided an operational update. “The first quarter marked an important strategic inflection point for TriSalus as we significantly strengthened our c...
-
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering...
-
Oklo Publishes First Quarter 2026 Financial Results and Business Update
SANTA CLARA, Calif.--(BUSINESS WIRE)--Oklo Inc. (NYSE: OKLO) (“Oklo” or “the Company”), an advanced nuclear technology company, today published its financial results and business update for the first quarter ended March 31, 2026. Oklo will host a conference call today, May 12, 2026, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time. Jacob DeWitte, Co-Founder and Chief Executive Officer, and Craig Bealmear, Chief Financial Officer, will speak on the call. A webcast of the call can be accessed b...
-
BW Investor Alert: Babcock & Wilcox Enterprises Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Defendants Allegedly Concealed Contract Risks: Levi & Korsinsky
NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP announces that a securities class action has been filed against Babcock & Wilcox Enterprises, Inc. (NYSE: BW). YOU MAY BE AFFECTED IF YOU: Purchased BW stock between November 5, 2025 and March 11, 2026 Lost money on your Babcock & Wilcox investment Submit your information to recover losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500. BW shares dropped $1.71 per share, or 11.59%, after a short seller ex...
-
STLA Investor Alert: Stellantis N.V. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Hid Deteriorating Trajectory: Levi & Korsinsky
NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP encourages investors who suffered losses in Stellantis N.V. (NYSE: STLA) to contact the firm. WHO IS AFFECTED: Those who purchased STLA securities between February 26, 2025 and February 5, 2026 may be entitled to recover damages. Find out if you are eligible to recover losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500. On February 6, 2026, Stellantis shares fell $2.26 per share, a decline of approximately 23....
-
MANSCAPED® Debuts The Beard Hedger® Plus and Refreshed Beard Care Routine
SAN DIEGO--(BUSINESS WIRE)--MANSCAPED®, the global men’s grooming company and lifestyle consumer brand, today announced the launch of The Beard Hedger® Plus alongside a reimagined collection of beard care essentials designed to support a complete grooming routine. Serving as the foundation of The Beard Hedger line, The Beard Hedger Plus offers an accessible entry point into MANSCAPED’s growing facial hair portfolio, while complementing the original trimmer, The Beard Hedger, which delivers expa...
-
MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After CEO Allegedly Certified Misleading Statements: Levi & Korsinsky
NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP alerts investors in Medpace Holdings Inc. (NASDAQ: MEDP) of a pending securities class action naming senior executives as individual defendants. Class Period: April 22, 2025 through February 9, 2026. Find out if you qualify to recover losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.Medpace shares fell $84.30 per share, a decline of more than 15.9%, after corrective disclosures allegedly revealed the Company's...